期刊文献+

低分子肝素联合化疗治疗高凝状态晚期直肠癌对血栓标志物的影响研究 被引量:3

Clinical Effect of Low Molecular Weight Heparin and Chemotherapy in the Thrombosis Marker for Patients with Advanced Rectal Carcinoma and Hypercoagulability
下载PDF
导出
摘要 目的探讨高凝状态晚期直肠癌患者采取低分子肝素联合化疗治疗对血栓标志物的影响。方法整群选取68例于2014年5月—2015年5月期间该院接收的伴高凝状态晚期直肠癌患者,根据治疗方案不同分为对照组(单纯化疗,n=34)与实验组(低分子肝素联合化疗,n=34),观察两组疗效及两组患者纤维蛋白水平、D-二聚体含量在治疗前后的变化。结果实验组较对照组临床有效率稍高(P>0.05),分别为70.6%、64.7%,差异无统计学意义;治疗后,对照组纤维蛋白原水平无变化,D-二聚体含量较疗前显著要高(P<0.05),分别为(4.96±1.42)、(0.68±0.22)μg/L,实验组治疗后纤维蛋白原水平较疗前显著要低(P<0.05),D-二聚体水平疗后显著降低(P<0.05),分别为(3.63±0.72)、(0.28±0.16)μg/L,与对照组比较均差异有统计学意义;两组骨髓抑制、消化道反应情况比较差异无统计学意义(P>0.05)。结论高凝状态的晚期直肠癌患者采用低分子肝素联合化疗治疗,能有效改善患者高凝状态,但对直肠癌的远期疗效尚需进一步研究观察。 Objective To study the clinical effect of low molecular weight heparin and chemotherapy in the thrombosis marker for patients with advanced rectal carcinoma and hypercoagulability.Methods Group selection 68 patients with advanced rectal carcinoma and hypercoagulability treated from May 2014 to May 2015 in our hospital were selected.The subjects were divided into two groups according to different therapies,34 cases each group.The control group took the chemotherapy;the test group took the low molecular weight heparin and chemotherapy.The clinical effect,the level of fibrinogen and D-dimer for two groups was observed.Results The clinical effective rate for test group(70.6%) was slightly higher than control group(64.7%)(P〈0.05);For control group,the level of fibrinogen and D-dimmer was(4.96±1.42)g/L and(0.68±0.22)μg/L.The level of fibrinogen before and after treatment was not significantly different;the content of Ddimer was significantly higher than before(P〉0.05).For test group,the level of fibrinogen and D-dimmer was(3.63±0.72)g/L and(0.28±0.16)μg/L.After treatment,the level of fibrinogen and D-dimer was significantly lower than before(P〈0.05);the incidence rate of bone marrow suppression and gastrointestinal reaction for two groups was not significantly different(P〉0.05).Conclusion For patients with advanced rectal carcinoma and hypercoagulability,the low molecular weight heparin and chemotherapy can improve the patient's hypercoagulability.However,the long-term effect shall be further explored.
作者 张念海
出处 《中外医疗》 2016年第24期61-63,共3页 China & Foreign Medical Treatment
关键词 血栓标志物 高凝状态 低分子肝素 晚期直肠癌 Thrombosis marker Hypercoagulability Low molecular weight heparin Advanced rectal carcinoma
  • 相关文献

参考文献8

二级参考文献80

  • 1何锡强,汪蓓,赵辉,孙晓雄.注射用血凝酶对髋关节置换术患者围术期出凝血功能影响的研究[J].中华创伤杂志,2004,20(11):685-687. 被引量:10
  • 2邓明扬,张广森,李斌,戴崇文,裴敏飞.血栓性血小板减少性紫癜患者血管内皮细胞标志物和溶血参数的动态分析及其临床意义[J].中华血液学杂志,2005,26(3):163-166. 被引量:8
  • 3郭小毛,梅欣,章倩.局部晚期乳腺癌的治疗进展[J].中国癌症杂志,2006,16(6):409-416. 被引量:35
  • 4张治云,凌沛学,王凤山,张天民.低分子肝素临床应用的研究进展[J].中国生化药物杂志,2006,27(4):253-255. 被引量:34
  • 5Fletcher JJ, Stetler W, Wilson TJ, et al. The clinical signifi- cance of peripherally inserted central venous catheter-related deep vein thrombosis. Neurocritieal Care, 2011, 15 ( 3 ): 134-137.
  • 6Verso M, Agnelli G,Berteglio S, et al. Enoxaparin for preven- tion of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol, 2005,23 (18) : 4057-4062.
  • 7Zacharski LR, Prandoni P, Monreal M. Warfarin versus low molecular weight heparin therapy in cancer patients. Oncolo- gist, 2005, 10 (1): 72-79.
  • 8Luciani A, Clement O, HalimiP, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients. Radiolo- gy, 2001, 220(23): 655-660.
  • 9Lodha A,Kamaluddeen M,Akierman A,et al. Role ofhemocoagulase in pulmonary hemorrhage in preterminfants : a systematic review [ J]. Indian J Pediatr,2011,78(7) : 838 -844.
  • 10Dai Q,Wang LL,Shao XH, et al. Clinical effectiveness ofmultiple-drug injection treatment in unruptured ectopicpregnancies : A retrospective study [ J]. J UltrasoundMed,2012,31(10) : 1627 -1634.

共引文献60

同被引文献20

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部